Page 58 - Read Online

Page 16 of 18 Qin et al. Hepatoma Res 2020;6:24 I http://dx.doi.org/10.20517/2394-5079.2020.04

through membrane-bound TGF-beta. Hepatology 2011;53:306-16.
79. Hong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, et al. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-
induced murine autochthonous hepatocellular carcinoma. Hepatology 2014;59:1448-58.
80. Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in
cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med 2011;11:564-81.
81. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, et al. Association between high-avidity T-cell receptors, induced by
alpha-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 2017;152:1395-
406.e10.
82. Zhang W, Liu J, Wu Y, Xiao F, Wang Y, et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic
homologous alpha fetoprotein in mice. Biochem Biophys Res Commun 2008;376:10-4.
83. Chen K, Wu Z, Zhao H, Wang Y, Ge Y, et al. XCL1/Glypican-3 fusion gene immunization generates potent antitumor cellular
immunity and enhances anti-PD-1 efficacy. Cancer Immunol Res 2020;8:81-93.
84. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, et al. Phase I trial of a glypican-3-derived peptide vaccine
for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res
2012;18:3686-96.
85. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular
carcinomas. Nat Genet 1998;18:65-8.
86. Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, et al. Human telomerase contains evolutionarily conserved catalytic and
structural subunits. Genes Dev 1997;11:3109-15.
87. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, et al. Cytotoxic T cell responses to human telomerase reverse
transcriptase in patients with hepatocellular carcinoma. Hepatology 2006;43:1284-94.
88. Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, et al. Immunological features of T cells induced by human telomerase
reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Lett 2015;364:98-105.
89. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell
responses in patients with hepatocellular carcinoma. J Immunol 2005;174:1709-16.
90. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans
after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
91. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, et al. Rapid induction of tumor-specific type 1 T helper cells in
metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med
2002;195:1279-88.
92. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a
systematic review and meta-analysis. Cytotherapy 2018;20:975-89.
93. Lu Z, Zuo B, Jing R, Gao X, Rao Q, et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular
carcinoma mouse models. J Hepatol 2017;67:739-48.
94. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, et al. Phase Ii study of autologous monocyte-derived mRNA
electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol
2016;34:1330-8.
95. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic
cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.
96. Nemunaitis J, Barve M, Orr D, Kuhn J, Magee M, et al. Summary of bi-shRNA/GM-CSF augmented autologous tumor cell
immunotherapy (FANG) in advanced cancer of the liver. Oncology 2014;87:21-9.
97. Pexa-Vec/Nexavar Combination Fails Phase III Trial in Liver Cancer. Available from: https://www.genengnews.com/news/pexa-vec-
nexavar-combination-fails-phase-iii-trial-in-liver-cancer/ [Last accessed on 21 Apr 2020]
98. Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in hepatocellular carcinoma: is there a light at the end of the
tunnel? Cancers (Basel) 2019;11:1078.
99. Yoo SY, Jeong SN, Kang DH, Heo J. Evolutionary cancer-favoring engineered vaccinia virus for metastatic hepatocellular carcinoma.
Oncotarget 2017;8:71489-99.
100. Ady JW, Heffner J, Mojica K, Johnsen C, Belin LJ, et al. Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills
sorafenib-resistant hepatocellular carcinoma efficiently. Surgery 2014;156:263-9.
101. Wang J, Xu L, Zeng W, Hu P, Zeng M, et al. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus
G47delta. Cancer Cell Int 2014;14:83.
102. Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination
immunotherapy. Nat Rev Cancer 2018;18:419-32.
103. Haanen JB, Robert C. Immune checkpoint inhibitors. Prog Tumor Res 2015;42:55-66.
104. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat
Rev 2015;41:868-76.
105. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
106. Zhang M, Pang HJ, Zhao W, Li YF, Yan LX, et al. VISTA expression associated with CD8 confers a favorable immune
microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer 2018;18:511.
107. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol
Hepato 2015;12:681-700.
108. Li H, Wu K, Tao K, Chen L, Zheng Q, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor